Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Location of rare cancer impacts survival, study suggests (opens in a new tab)

medicalxpress.com · 2026-10-26

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 6 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Six of seven claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 6 supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredClinical trials of leiomyosarcoma are often performed without accounting for where the cancer arises in the body, and the findings suggest location should be considered when analyzing studies of new therapies.View evidenceHide evidence

Why this verdict

The abstract profile supports the implication that future multi-site trials should account for anatomical location when designing and interpreting studies. However, the specific assertion that leiomyosarcoma trials are 'often performed without accounting' for tumor origin is not verifiable from the supplied abstract-level paper profile.

1

Study evidence

Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%

“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
Claim 2 of 7SupportedA rare, aggressive cancer called leiomyosarcoma behaves differently depending on where it is found in the body.View evidenceHide evidence

Why this verdict

The headline-level claim is broadly supported by the abstract profile: anatomical site was independently associated with survival, and a secondary genomic analysis found site-associated ATRX mutation enrichment. The supplied abstract profile does not separately substantiate the background wording that leiomyosarcoma is 'rare' and 'aggressive,' but the core location-dependent behavior claim is supported.

1

Study evidence

Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%

“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
2

Study evidence

ATRX mutations were enriched in uterine leiomyosarcoma compared with other anatomical sites in a pooled analysis of publicly available sequencing data.adjusted P < .001

“ATRX mutations were enriched (adjusted P < .001) in uterine cases compared with other sites in a pooled analysis of publicly available sequencing.”
Claim 3 of 7SupportedLeiomyosarcomas of the uterus, urinary tract and trunk had the poorest survival rates, compared with cancers of the limbs, head and neck, and male reproductive tract.View evidenceHide evidence

As statedpoorest survival rates

Why this verdict

The profile states that, after adjustment, uterus, urinary tract, and trunk tumors were among the highest-risk sites, while limb, head and neck, and male reproductive tract tumors had more favorable outcomes. The story's wording is somewhat stronger than 'among the highest-risk,' but it tracks the abstract's stated risk grouping.

1

Study evidence

Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%

“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
Claim 4 of 7SupportedScientists studied 11,700 leiomyosarcoma patients and found major differences in patient outcomes between tumor sites.View evidenceHide evidence

As stated11,700 patients

Why this verdict

The paper profile reports a cohort of 11,751 patients; the story's '11,700' is a reasonable rounded figure. The abstract supports major outcome differences between tumor sites through adjusted survival comparisons and multivariable analysis.

1

Study evidence

Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%

“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
Claim 5 of 7SupportedThe findings indicate that tumor location could provide clinically meaningful information on disease risk for those with leiomyosarcoma, beyond cancer stage and grade.View evidenceHide evidence

Why this verdict

The abstract supports the claim that anatomical location adds prognostic information: site was independently associated with survival in multivariable analysis adjusting for demographic and tumor factors, and the paper frames this as relevant to risk and trial design. The story appropriately hedges this as 'could provide' clinically meaningful information.

1

Study evidence

Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%

“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
Claim 6 of 7SupportedBlack patients, those from lower-income households and widowed individuals experienced significantly poorer outcomes.View evidenceHide evidence

As statedsignificantly poorer outcomes

Why this verdict

The profile reports that race, marital status, and household income were independently associated with outcome, and specifically that Black patients, widowed patients, and those in the lowest income group had substantially shorter survival after adjustment.

1

Study evidence

Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%

“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
Claim 7 of 7SupportedThe study also identified differences in the underlying biology of tumors in different locations, including a specific genetic mutation being more common in uterine tumors.View evidenceHide evidence

Why this verdict

The abstract profile supports a site-linked genomic difference: ATRX mutations were enriched in uterine cases compared with other sites in pooled public sequencing data. The story does not name ATRX or mention that this was a separate pooled public sequencing analysis with limited abstract-level methods, but the core claim is supported.

1

Study evidence

ATRX mutations were enriched in uterine leiomyosarcoma compared with other anatomical sites in a pooled analysis of publicly available sequencing data.adjusted P < .001

“ATRX mutations were enriched (adjusted P < .001) in uterine cases compared with other sites in a pooled analysis of publicly available sequencing.”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

7 things the story did carry across
  • Large retrospective cohort of leiomyosarcoma patients: 11,751 patients with median follow-up of 8.4 years.
  • Anatomical site was independently associated with survival in multivariable analysis adjusting for demographic and tumor factors.
  • Adjusted site-specific risk pattern: uterus, urinary tract, and trunk were among the highest-risk sites; limbs, head and neck, and male reproductive tract had more favorable outcomes.
  • Race, marital status, and household income were independently associated with survival, with Black, widowed, and lowest-income patients having shorter survival.
  • Secondary genomic analysis found ATRX mutation enrichment in uterine leiomyosarcoma using pooled publicly available sequencing data.
  • Implication for future multi-site clinical trials: anatomical location should be accounted for in design and interpretation.
  • Observational retrospective secondary-data design limits causal interpretation and leaves potential residual confounding.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCharacterize survival differences across leiomyosarcoma anatomical sites and identify patient/tumor characteristics independently associated with survival to inform multi-site clinical trial design.retrospective cohort analysis (secondary data)Expand

In plain English

Large retrospective cohort analysis of 11,751 leiomyosarcoma patients with median follow-up 8.4 years found marked heterogeneity in patient and tumor characteristics and in survival across anatomical sites. Multivariable time-to-event analysis (adjusting for demographic and tumor factors) identified anatomical site, tumor grade, race, marital status, and household income as independent predictors of outcome. After adjustment, uterine, urinary tract, and trunk tumors were among the highest-risk sites for poorer survival, while limbs, head and neck, and male reproductive tract tumors had more favorable outcomes. A pooled analysis of publicly available sequencing data found enrichment of ATRX mutations in uterine cases (adjusted P < .001).

Key findings

  • Anatomical site distribution in the cohort: uterus 36.3%, limbs 16.6%, superficial trunk 10.8%, retroperitoneum 9.2%.uterus 36.3%; limbs 16.6%; superficial trunk 10.8%; retroperitoneum 9.2%
  • Multivariable analysis identified anatomical site, tumor grade, race, marital status, and household income as independent predictors of survival.
“We analyzed a study cohort of 11 751 patients with leiomyosarcoma arising across a range of anatomical sites.”
What this piece can’t prove
  • Observational retrospective cohort using secondary data; potential for residual confounding inherent to non-randomized analyses.
  • Abstract does not specify the exact survival model, covariate definitions/coding, or report numerical effect estimates (e.g., hazard ratios and confidence intervals).

2 further details could not be confirmed from the summary.

2secondary dataAssess whether key genomic alterations (ATRX mutations) differ by anatomical site using pooled publicly available sequencing data.pooled sequencing analysisExpand

In plain English

Pooled analysis of publicly available tumor sequencing data reported ATRX mutations to be enriched in uterine leiomyosarcoma compared with other anatomical sites (adjusted P < .001).

Key findings

  • ATRX mutations were enriched in uterine leiomyosarcoma compared with other anatomical sites in a pooled analysis of publicly available sequencing data.adjusted P < .001
“ATRX mutations were enriched (adjusted P < .001) in uterine cases compared with other sites in a pooled analysis of publicly available sequencing.”
What this piece can’t prove
  • Pooled public sequencing datasets may be heterogeneous in sequencing platforms, tumor selection, and annotation.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation

OrthoMedia · 2021 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.